Open AccessP914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
Author(s) -
Kastritis E.,
Palladini G.,
Dimopoulos M. A.,
Jaccard A.,
Merlini G.,
Theodorakakou F.,
Fotiou D.,
Minnema M. C.,
Wechalekar A.,
Gkolfinopoulos S.,
Manousou K.,
Sonneveld P.,
Schönland S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846524.06649.c4
Subject(s) - medicine , tolerability , al amyloidosis , refractory (planetary science) , amyloidosis , bortezomib , dosing , oncology , multiple myeloma , gastroenterology , surgery , adverse effect , immunoglobulin light chain , antibody , immunology , physics , astrobiology